plications and mortality related to pneumonia [5] [6] [7] [8] . Thus, knowledge about the microbial epidemiology of each intensive care unit (ICU) is extremely important to ensure the choice of an appropriate empirical antimicrobial therapy. However, microbiology and the resistance patterns are not the same in different hospitals or between different departments within a hospital [9] . In addition, the etiology of ventilator-associated pneumonia (VAP) may vary substantially between different geographic sites in patients with similar epidemiological risk factors [10] .
The treatment guidelines published by scientific societies are an invaluable help to begin an adequate empirical antimicrobial therapy in infected critically-ill patients. The current 2005 American Thoracic Society (ATS)-Infectious Disease Society of America (IDSA) guidelines for the management of adults with HAP, VAP, and health care-associated pneumonia focused on the epidemiology and pathogenesis of HAP, emphasized modifiable risk factors for infection, and reviewed the microbiology of HAP with an emphasis on "potentially drug-resistant" microorganisms (PRMs) [1] . These guidelines classified patients into 2 groups on the basis of time of onset of infection (early onset vs late onset) and the presence of risk factors for infection with a PRM.
Despite extensively diffused, these guidelines have never been validated in the clinical practice. We therefore assessed the efficacy of the current ATS/IDSA guidelines to predict the infecting pathogens and validated the adequacy of these guidelines for the choice of the empirical antibiotic strategy and outcome in ICU patients. Because the 2005 guidelines introduced substantial changes in the risk factors for infection by PRM, we also compared these guidelines with the former 1996 ATS guidelines for HAP in adults [11] .
METHODS

Study population. The study was conducted in 6 specialized
ICUs of an 800-bed university hospital. The investigators made daily rounds in the different ICUs. Patients aged 118 years who had been admitted to these ICUs for у48 h with clinical suspicion of HAP were prospectively and consecutively included in the study. Patients with major immunosuppression [12] were excluded. The ethics committee of the institution approved the study, and written informed consent was obtained from patients or relatives.
Definition of pneumonia, microbiologic processing, and antimicrobial treatment. The clinical suspicion of pneumonia was based on either (1) clinical criteria (new or progressive radiological pulmonary infiltrate plus у2 of the following characteristics: temperature, 138ЊC or !35.5ЊC; leukocyte count, 112,000 cells/mm 3 or !4000 cells/mm 3 ; or purulent respiratory secretions [13, 14] ) or (2) a simplified Clinical Pulmonary Infectious Score 15 points [15] . VAP was diagnosed in patients with previous invasive mechanical ventilation for у48 h.
The microbiologic evaluation included the collection of at least 1 lower respiratory airway sample by sputum, tracheobronchial aspirate, or bronchoscopy [16] or by blind bronchoalveolar lavage [17] within the first 24 h after inclusion. The same sampling method was performed after 3 days if clinically indicated. Blood cultures and cultures of pleural fluid specimens, if puncture was indicated, were also undertaken. Microbiologic confirmation of pneumonia was defined by the presence of у1 potentially pathogenic microorganism (PPM) in respiratory samples above predefined thresholds (for bronchoalveolar lavage specimens, 110 4 CFU/mL; for sputum or tracheobronchial aspirate specimens, 110 5 CFU/mL) [18] ; in pleural fluid specimens; or in blood cultures, if an alternative cause of bacteremia was ruled out. Microbial identification and susceptibility testing were performed by standard methods [19] . Pneumonia was considered to be caused by PRM if methicillinresistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Acinetobacter baumannii, or Stenotrophomonas maltophilia were identified [1, 20, 21] . Polymicrobial pneumonia was defined as identification of 11 PPM as causative agents. The initial empirical antimicrobial treatment was administered in accordance with local adaptation of the ATS/IDSA guidelines [1] and was subsequently revised according with the microbiologic results.
Validation of the ATS/IDSA guidelines. According to the guidelines, we aggregated patients into group 1 (early-onset pneumonia without risk factors for PRM infection) and group 2 (late-onset pneumonia or early-onset pneumonia with risk factors for PRM infection) [1] . We assessed the adequacy of the guidelines to predict the isolated pathogens according to each patient's category [1] . If the isolated pathogen corresponded to the expected one, the microbial prediction was considered adequate.
Patients were also aggregated into different groups depending on whether the initial empirical antimicrobial treatment chosen by the attending physicians fitted the treatment suggested by the guidelines. These were classified as adherence or not to the guidelines. The prediction of the isolated pathogens and the treatment adherence were also assessed for the previous 1996 ATS guidelines on HAP [11] . These guidelines classified patients into 3 groups, as follows: group 1, mild-to-moderate HAP, no usual risk factors, onset any time, or early-onset, and severe HAP; group 2, mild-to-moderate HAP with risk factors and onset any time; and group 3, late-onset, severe HAP or earlyonset HAP with risk factors.
The empirical antimicrobial treatment was considered adequate when the isolated pathogens were susceptible in vitro to у1 of the antimicrobials administrated. For P. aeruginosa infection, adequate treatment needed a combination of 2 active antibiotics against the isolated strain [22] .
The initial response to treatment was evaluated after 72 h of antimicrobial treatment. Nonresponse was considered if у1 of the following criteria were present: (1) no improvement of the arterial O 2 tension to inspired O 2 fraction ratio or need for intubation because of pneumonia (defined as need for intubation after 24 h after the commencement of antibiotics); (2) persistence of fever (temperature, у38ЊC) or hypothermia (temperature, !35.5ЊC), together with purulent respiratory secretions; (3) increase in the pulmonary infiltrates on chest radiograph of у50%; or (4) occurrence of septic shock [23] or multiple-organ dysfunction syndrome, defined as у3 organ system failures [24] not present on day 1 [25, 26] . An effort was made to rule out causes not related to pneumonia. In Tracheostomy at admission 0 (0) 23 (10) .053
Cause of ICU admission .008
Postoperative respiratory failure 8 (21) 78 (33) Hypercapnic respiratory failure 4 (11) 24 ( patients with initial nonresponse to treatment, cultures of respiratory samples and blood were obtained again, and the empirical antimicrobial treatment was revised. Data collection. All relevant data from the medical records and bedside flow charts of patients, including clinical, laboratory, radiology, and microbiology information, were collected at admission and at onset of pneumonia, and patients' followup was extended to death or hospital discharge. Special emphasis was made in searching all risk factors for PRM causing HAP, including those for health care-associated pneumonia, as defined in the 2005 ATS/IDSA guidelines [1] .
Statistical analysis. 
RESULTS
Patients' characteristics.
We included 276 patients; 38 were allocated to group 1, and 238 we allocated to group 2. The patients' characteristics at ICU admission and at onset of pneumonia are shown in Tables 1 and 2 . Except for the rates of underlying chronic heart disorders, previous hospital admissions and use of antibiotics and corticosteroids, tracheostomy at admission, and the hospital stay prior to onset of pneumonia, patients from groups 1 and 2 were similar. Microbiologic findings. Pneumonia was microbiologically confirmed in 153 (55%) cases. The proportion of patients with etiological diagnosis, polymicrobial pneumonia, and the individual PPM isolated, including PRM, were similar between the two groups (Table 3) .
Ten patients (26%) from group 1 had PRM, despite the absence of risk factors for these microorganisms according to the guidelines [1] . Their reason for ICU admission was post- operative respiratory failure in 4 cases, decreased consciousness and multiple trauma in 2 cases each, and acute coronary syndrome and hypercapnic respiratory failure in 1 each. The patients' comorbidities included chronic heart disease in 5 cases, chronic obstructive pulmonary disease (COPD) and cancer in 3 cases each, and chronic liver disease and diabetes mellitus in 1 case each. Blood cultures positive for pathogens considered causative of pneumonia were found in 5 patients (13%) from group 1 (methicillin-sensitive S. aureus [MSSA] , MRSA, Streptococcus pneumoniae, Enterobacter species, and Bacteroides fragilis) and 23 patients (10%) from group 2 (MSSA and P. aeruginosa in 5 cases, and Klebsiella species and Escherichia coli in 3 cases each, among others). Pleural fluid culture results were positive for 2 patients from group 1 (MRSA and Candida species) and 9 patients from group 2 (MRSA and MSSA in 3 cases each, P. aeruginosa in 2 cases, and Streptococcus milleri in 1 case).
Aspergillus fumigatus was considered the causative agent in 8 patients from group 2. Four of them had COPD, 2 had cancer, and 1 had chronic liver disease. Four had received corticosteroids.
Microbial prediction. The ATS/IDSA guidelines successfully predicted the causative microorganisms in 131 patients (86%) with a defined etiologic diagnosis. The microbial prediction was better for patients from group 2 (P ! .001) ( Table  4 ). The guidelines failed to predict 14 pathogens in 12 patients allocated to group 1 (MRSA and P. aeruginosa in 6 cases; Candida species and B. fragilis in 1 case each) and in 10 patients allocated to group 2 (A. fumigatus in 8; S. milleri and Fusobacterium species in 1 case each).
Patients were reclassified according to the groups defined in the 1996 ATS guidelines [11] . Thirty-three out of 38 patients from group 1 had risk factors for PRM according to the 1996 guidelines; hence the microbial prediction resulted better than the 2005 guidelines for patients from group 1, in whom microbial prediction increased to 21 (88%) (P p .014).
Nine patients from group 1 with etiologic pathogens wrongly predicted by the 2005 guidelines (MRSA in 6 cases and P. aeruginosa in 5 cases, with isolation of both pathogens in 2 cases) were correctly predicted by the 1996 guidelines. No patient wrongly predicted by the 1996 guidelines was rightly predicted by the 2005 guidelines.
Length of stay, mortality, treatment adequacy, response to treatment, and adherence to the guidelines. The ICU and hospital stay were longer in patients from group 2 (P ! .001). There was a nonsignificant trend toward a lower hospital mortality rate for patients from group 1 ( Table 4) .
The empirical antimicrobial treatment was adequate in 114 patients (75%) who had a defined etiologic diagnosis, and 108 (39%) patients did not respond adequately to the empirical antimicrobial treatment. The adequacy and the initial clinical response to the empirical treatment were similar between groups 1 and 2. Inadequate treatment was associated to more nonresponse to the initial treatment (24 The pathogens most frequently associated to inadequate treatment were P. aeruginosa in 18 cases, MRSA in 11, A. fumigatus in 5, and S. maltophilia in 4. Likewise, the pathogens most frequently isolated in nonresponders to the initial treatment were P. aeruginosa in 26 cases, MSSA in 14, MRSA in 12, E. coli and Enterobacter species in 7 each, S. maltophilia in 5, and S. pneumoniae and A. fumigatus in 4 each. In 40 nonresponders (36%), no etiologic pathogen was isolated.
Adherence of the empirical antimicrobial treatment chosen by the attending physicians to the 2005 ATS/IDSA guidelines occurred in 160 cases (58%); the adherence was higher in patients from group 2 (P ! .001). Adherence to the guidelines resulted in more frequent treatment adequacy than lack of adherence (P p .013) ( Table 5) ; this relationship was observed in patients from group 2 but not in those from group 1. In group 2, guidelines adherence was associated with a trend to better initial response to treatment (P p .087). When patients were reclassified according to the risk factors for PRM defined in the 1996 ATS guidelines, the adherence to the empirical antimicrobial treatment recommended by the 2005 guidelines substantially improved in patients from group 1 (from 7 [18%] to 16 [42%]; P p .047) ( Table 4 ). The better treatment adequacy associated with guidelines adherence was more pronounced when patients were classified according to the risk factors for PRM defined by the 1996 ATS guidelines (P p .002) (Table 5 ). Again, this relationship was observed in patients from group 2 only, and guidelines adherence was associated with better initial response to treatment in this group (P p .052). However, adherence to both guidelines did not influence the hospital mortality and length of stay.
DISCUSSION
Although the current 2005 ATS/IDSA guidelines for HAP [1] had an overall good rate of microbial prediction, the previous 1996 ATS guidelines [11] yielded better predictions of the presence of PRM. The adherence of the empirical antimicrobial treatment to both guidelines resulted in more treatment adequacy in patients from group 2 only. Guidelines adherence tended to improve the clinical response to the empirical treatment in this group, but did not influence the length of stay or mortality.
The choice of the empirical antimicrobial treatment is often based on the recommendations of published guidelines from scientific societies. However, the guidelines are based on scientific evidence plus experts' recommendations, and therefore, validation in the clinical setting is advisable. We had previously assessed the microbial prediction and treatment adequacy of the previous ATS guidelines for the management of HAP [21] . In this study, the 1996 guidelines [11] showed a good predictive capacity for the infecting pathogens. However, the treatment adequacy was low because of the presence of highly drugresistant microorganisms in the cohort [21] .
These guidelines were subsequently revised jointly with the IDSA with substantial changes in the risk factors for infection caused by PRM [1] . The new 2005 ATS/IDSA guidelines successfully predicted the causative pathogens in 86% cases from the present study. However, 12 cases (50%) from group 1 with a defined etiological diagnosis were wrongly predicted by these guidelines. Among them, the etiology of pneumonia in 9 patients with PRM (MRSA and P. aeruginosa) was correctly predicted when the risk factors for PRM defined by 1996 ATS guidelines, instead of those defined by the 2005 guidelines, were applied to our population. These 9 patients had risk factors for infection caused by PRM according with the 1996 ATS guidelines [11] , such as previous prolonged and complicated surgery in 5 cases, chronic alcohol abuse in 4, COPD and solid cancer in 3 each, and diabetes mellitus, chronic liver disease, and prolonged treatment with corticosteroids in 1 case each. None of these were considered risk factors for PRM in the 2005 ATS/ IDSA guidelines [1] .
Both guidelines failed in predicting anaerobes and fungi in our population, particularly A. fumigatus. Therefore, predictors for pulmonary aspergillosis in patients without major immu-nosuppression should be considered in future guidelines. However, etiologies of all patients with PRM except 1 were correctly predicted when the 1996 guidelines were applied [11] . The accuracy of these guidelines, particularly the high specificity in excluding the presence of PRM, had been assessed in previous reports [21, 27] . Therefore, the usual risk factors leading to pneumonia defined by the 1996 guidelines [11] appear more accurate than the risk factors for PRM defined by the 2005 guidelines [1] in predicting the etiology of HAP in the ICU. The usefulness of the 1996 guidelines may also be improved by local adaptations to specific settings as suggested in 2 studies [28, 29] .
The reasons for nonadherence to guidelines were different between both groups. The poor microbial prediction of the 2005 ATS/IDSA guidelines for patients from group 1 in our study is in line with the low adherence of the attending physicians to these guidelines. It suggests that there is not much trust among physicians in excluding risk factors for PRM according to the definitions of the 2005 guidelines. Indeed, we observed that most patients from group 1 were treated similarly than patients from group 2, and this was the reason for the low adherence to the 2005 guidelines in this group. By contrast, the 36% lack of treatment adherence in group 2 was mainly due to the use of antibiotic combinations not recommended by the guidelines.
Adherence of the empirical treatment to both guidelines resulted in better treatment adequacy only for patients from group 2, as shown in Table 5 . This effect was more pronounced when the risk factors for PRM of the 1996 ATS guidelines were applied in our population. Similar to previous investigations [30, 31] , the most frequent pathogens causing pneumonia (P. aeruginosa, MRSA, and MSSA) were the same in patients with either early-or late-onset pneumonia. Rather than the time of onset, a proper identification of risk factors for specific pathogens is crucial in choosing an appropriate empirical treatment. Therefore, we suggest that future guidelines for the treatment of patients with HAP consider the risk factors for PRM defined by the 1996 ATS guidelines.
Although mortality was not significantly higher in those patients who were inadequately covered by the initial antimicrobial therapy, we observed a worse initial clinical response, which was strongly associated with higher mortality, in them. This stresses the crucial role of an initial adequate therapy for the outcome of these patients, in line with previous publications [5] [6] [7] [8] . However, although the normal pattern of resolution of VAP has been described elsewhere [15, 32] , the definition of initial nonresponse to empirical treatment, although used in previous investigations [25, 26] , needs further prospectively validation.
A limitation of this study is that our population consists of ICU patients; therefore, it did not include patients with mildto-moderate HAP. Patients with HAP outside the ICU have lower incidence of PRM and higher incidence of "communityacquired PPM," such as S. pneumoniae and Legionella pneumophila than in the present study [33] . Whether our findings may be extrapolated to non-ICU patients with HAP needs further assessment. A potential approach for future guidelines is to provide different recommendations for patients inside and outside the ICU. Another limitation is that this is a monocenter study and may not be representative for the majority of ICUs worldwide. Finally, the number of patients in group 1 is small, and therefore, these results should be confirmed in larger populations.
In conclusion, the current 2005 ATS/IDSA guidelines do not provide a good microbial prediction for PRMs in group 1. This prediction resulted better when reclassifying patients according to the 1996 ATS guidelines. The reasons for nonadherence to the antibiotic recommendations were different for both groups. In group 2, adherence to both guidelines resulted in better treatment adequacy and a trend to a better clinical response, but did not influence mortality.
